These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37271721)

  • 21. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
    Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
    J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
    J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid aβ to tau ratio and postoperative cognitive change.
    Xie Z; McAuliffe S; Swain CA; Ward SA; Crosby CA; Zheng H; Sherman J; Dong Y; Zhang Y; Sunder N; Burke D; Washicosky KJ; Tanzi RE; Marcantonio ER
    Ann Surg; 2013 Aug; 258(2):364-9. PubMed ID: 23732272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.
    Almeida RP; Schultz SA; Austin BP; Boots EA; Dowling NM; Gleason CE; Bendlin BB; Sager MA; Hermann BP; Zetterberg H; Carlsson CM; Johnson SC; Asthana S; Okonkwo OC
    JAMA Neurol; 2015 Jun; 72(6):699-706. PubMed ID: 25893879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer's Disease.
    Lojo-Ramírez JA; Guerra-Gómez M; Marín-Cabañas AM; Fernández-Rodríguez P; Bernal Sánchez-Arjona M; Franco-Macías E; García-Solís D
    J Alzheimers Dis; 2024; 97(1):447-458. PubMed ID: 38143353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
    Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
    Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.